ClinicalTrials.gg
CompletedNCT01394991Updated Apr 5, 2012Results posted

A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia

A Phase 4 interventional study of Epoetin alfa 450 IU/kg once a week and Epoetin alfa 150 IU/kg 3 times a week in Anemia and Neoplasms, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-05.

Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
504
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 126 studies testing Epoetin Alfa in Anemia — 2 open to participants now, 3 under way, 2 of them phase 3. Epoetin Alfa · Anemia.

Enrollment
7th of 112
504 · median 71
Started
2006
with 7 others
Phase 4
20 of 126
none open now
Registered
107th of 126
by date
Lead sponsor
53 of 126
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Among the 126 studies testing Epoetin Alfa in Anemia, this one is the 7th largest by enrollment of the 112 interventional ones that give a count, is one of 8 that started in 2006, is one of 20 in phase 4, and was the 107th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

2 of the 126 studies testing Epoetin Alfa in Anemia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Epoetin Alfa

Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing Epoetin Alfa in Anemia, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety of epoetin alfa in patients with cancer who have chemotherapy-related anemia.

Read the detailed description

Epoetin alfa is an agent similar to a hormone produced in the kidney (ie, erythropoietin) that functions to increase the amount of red blood cells made in the bone marrow. This is a randomized (study drug assigned by chance), open-label (patients and their doctors will know the identity of study drug administered), safety study of 2 dosing regimens (doses and schedules) of epoetin alfa administered to patients with cancer who have chemotherapy-related anemia. Anemia is a lack of red blood cells that can result in symptoms of weakness, shortness of breath, fatigue, tiredness, and decreased activity. The primary outcome measure in the study is the number of patients in each treatment group with at least 1 clinically relevant and objectively confirmed (adjudicated) thrombovascular event (TVE) reviewed by an independent adjudication committee from Day 1 (baseline or the day of the first dose) through Week 16. An external review of relevant clinical data and medical imaging studies by an Adjudication Committee will be performed in a blinded fashion for confirmation of TVEs. The Adjudication Committee will confirm TVEs by reviewing all images (X-ray, Computed tomography [CT] scan, ultrasound, Magnetic Resonance Imaging [MRI] scan, etc) and other diagnostic procedures auch as coagulation tests or electrocardiograms in combination with a clinical patient profile as described for each specific type of TVE. Only TVEs that are determined by the Adjudication Committee to be clinically relevant and objectively confirmed will be counted in the analysis for the primary endpoint. Approximately 500 patients, who have cancer, are receiving chemotherapy, and are anemic, will take part in the study. Patients will participate in the study for up to 32 weeks (this includes a 2-week screening period to determine eligibility for the study, a 26-week treatment period, and a 4-week follow-up period to have end-of-study assessments [tests] performed). The length of participation in the study depends on the length of time the patient is receiving chemotherapy and epoetin alfa; patients in the study may receive up to a maximum of 26 weeks of treatment with epoetin alfa. Patients will be randomly assigned (assigned by chance like flipping a coin) to 1 of 2 treatment groups (Epoetin Alfa QW or Epoetin Alfa TIW). Patients assigned to the Epoetin Alfa QW Group will receive epoetin alfa at an initial dosage of 450 IU/kg once a week and patients assigned to Epoetin Alfa TIW Group will receive epoetin alfa 150 IU/kg 3 times a week by subcutaneous (underneath the skin) injection. Injections will be given preferably on Monday for patients in the Epoetin Alfa QW Group and on Mondays, Wednesdays, and Fridays for patients in the Epoetin Alfa TIW Group. During the study, patients will visit the study center weekly to have a blood sample collected to measure the amount of hemoglobin (red blood cells) in the blood. Depending on the hemoglobin level, the dose of epoetin alfa may be increased or decreased. Regardless of treatment group, if anemia does not improve in patients after 4 weeks of treatment, the dose of epoetin alfa will be increased to 300 IU/kg 3 times a week. If anemia does not improve after 4 weeks at the increased dose level of epoetin alfa (300 IU/kg 3 times a week), treatment with epoetin alfa will be stopped. In addition, during the study, patients may also receive treatment with iron supplements if the level of iron in the blood is low. During the study, safety will be monitored by evaluating adverse events and findings from clinical laboratory tests, 12-lead electrocardiograms (ECGs), blood pressure measurements, and physical examinations. Patients will receive epoetin alfa at an initial dose of 450 IU/kg once a week or 150 IU/kg 3 times a week by subcutaneous injection, preferably in the abdomen, for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks. Injections for Epoetin Alfa QW Group will be at the study center and for Epoetin TIW Group, the 1st weekly injection will be at the study center and the 2nd and 3rd weekly injections will be at the study center or at home by self-administration.

03

Conditions studied

  • Anemia
  • Neoplasms

Keywords

  • Epoetin alfa (EPREX, ERYPO)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any nonmyeloid tumor confirmed by cytology and/or histology
  • Day 1 baseline (Hb) level \<=11 g/dL
  • Expected to receive at least 12 weeks of chemotherapy after enrollment into the study
  • (ECOG) performance status \<= 2

Exclusion criteria

Exclusion Criteria:

  • History of active second cancer except for adequately treated skin cancer and in situ (pre-invasive) cervical cancer
  • History of deep venous thrombosis (DVT) (blood clots in the veins of the thighs or legs) or pulmonary embolism (PE) (blood clot in the lungs) within 12 months before study entry or at any time if the event is related to the current cancer, which is defined as diagnosis of the cancer within 3 months of a DVT/PE episode or a DVT/PE following the cancer diagnosis/treatment
  • History of cardiovascular accident (CVA), (TIA) (stroke), acute coronary syndrome (ACS) (a condition indicating damage to the heart), or other arterial thrombosis (blood clots) within 6 months before study entry
  • Onset of seizures within 3 months before randomization or poorly controlled seizures
  • Brain tumor or from another or cardiac disease that is markedly or completely limiting, uncontrolled hypertension (high blood pressure), or anemia (a lack of red blood cells in the blood) for reasons other than cancer or chemotherapy
  • Specifically excluded concomitant medications or therapies including prophylactic anticoagulation therapy for recurrence of prior thrombovascular event (TVE) (warfarin, unfractionated heparin, low molecular weight heparin [LMWH], except for prevention of central venous catheter thrombosis at doses specified in the protocol, direct thrombin inhibitors, or anti- drugs [e.g., clopidogrel or ticlopidine]), except for prophylaxis in patients with known cardiovascular disease
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
504 participants (actual)

Study arms

  • Experimental
    001

    Epoetin alfa 450 IU/kg once a week (QW) 450 IU/kg once a week (QW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks

    Drug: Epoetin alfa 450 IU/kg once a week · Drug: Epoetin alfa 450 IU/kg once a week (QW)

  • Experimental
    002

    Epoetin alfa 150 IU/kg 3 times a week (TIW) 150 IU/kg 3 times a week (TIW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.

    Drug: Epoetin alfa 150 IU/kg 3 times a week · Drug: Epoetin alfa 150 IU/kg 3 times a week (TIW)

Interventions

  • DrugEpoetin alfa 450 IU/kg once a week

    Drug page: Epoetin Alfa

    450 IU/kg once a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.

  • DrugEpoetin alfa 150 IU/kg 3 times a week

    Drug page: Epoetin Alfa

    150 IU/kg 3 times a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.

  • DrugEpoetin alfa 450 IU/kg once a week (QW)

    Drug page: Epoetin Alfa

    450 IU/kg once a week (QW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks

  • DrugEpoetin alfa 150 IU/kg 3 times a week (TIW)

    Drug page: Epoetin Alfa

    150 IU/kg 3 times a week (TIW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.

06

What researchers measure

Primary outcomes

  1. Number of Participants With at Least 1 Clinically Relevant and Objectively Confirmed Thrombovascular Event From Randomization Through Week 16

    Clinically relevant and objectively confirmed thrombovascular event (TVE) was determined by the Adjudication Committee from randomization through Week 16. Clinically relevant TVEs were defined as deep vein thrombosis (DVT) of the limbs; thromboses of other major veins; pulmonary embolism (PE);acute coronary syndrome (ACS);ischemic stroke of arterial or cardiac origin; cerebral venous thrombosis; and arterial thrombosis. Objectively confirmed was defined as the confirmation of the clinical diagnosis of a TVE by appropriate medical imaging studies and laboratory tests.

    Time frame: from randomization through Week 16

Secondary outcomes

  1. Number of Positively Adjudicated Thrombovascular Events

    The number of participants who have at least 1 clinically relevant and objectively confirmed (adjudicated) thrombovascular event (TVE) during the study.

    Time frame: during the study (randomization through week 26)

  2. Time to First Positively Adjudicated Thrombovascular Event

    Analysis of time to first positively adjudicated thrombovascular event (TVE) measured from the date of randomization to the date of the first clinically relevant and objectively confirmed TVE as determined by the Adjudication Committee. Median time is non-estimable because of too few events, incidence was reported instead.

    Time frame: during the study (randomization through week 26)

  3. Number of Suspected Thrombovascular Events

    Number of participants who have at least 1 suspected thrombovascular events (TVEs) during the entire study. Suspected TVEs were defined as suspected TVEs during the entire study, whether clinically relevant and objectively confirmed by the Adjudication Committee or not, whether confirmed by the investigator or not.

    Time frame: during the study (randomization through week 26)

  4. Time to First Suspected Thrombovascular Event

    Analysis of time to first suspected thrombovascular event (TVE) measured from the date of randomization to the date of the first suspected TVE during the study. Median time is non-estimable because of too few events, incidence was reported instead.

    Time frame: during the study (randomization through week 26)

  5. Mortality

    Number of participants who died during the study.

    Time frame: during the study (randomization through week 26)

  6. Number of Hemoglobin Responders

    Hemoglobin response was defined as a hemoglobin increase of ≥2 g/dL from baseline or reaching a hemoglobin concentration of 12 g/dL, regardless of dose adjustment.

    Time frame: during the study (randomization through week 26)

  7. Red Blood Cell Transfusions

    The number of participants who received at least 1 red blood cell (RBC) transfusion (packed RBC or whole blood) during the study.

    Time frame: during the study (randomization through week 26)

07

Results

Posted Jul 15, 2011

Participant flow

This is a randomized, open-label, multicenter study evaluating thrombovascular events in participants with cancer receiving chemotherapy and administered Epoetin Alfa once weekly (QW) or three times a week (TIW) for the treatment of anemia.

Participant flow — Overall Study
MilestoneEpoetin Alfa QWEpoetin Alfa TIW
Started242262
Completed183190
Not completed5972
Withdrew: Adverse event04
Withdrew: Lack of efficacy57
Withdrew: Lost to follow-up68
Withdrew: Physician decision13
Withdrew: Protocol violation11
Withdrew: Withdrawal by subject2017
Withdrew: Chemotherapy termination1015
Withdrew: Disease progression77
Withdrew: Prematurely termination of trial910

Outcome measures

PrimaryNumber of Participants With at Least 1 Clinically Relevant and Objectively Confirmed Thrombovascular Event From Randomization Through Week 16

Clinically relevant and objectively confirmed thrombovascular event (TVE) was determined by the Adjudication Committee from randomization through Week 16. Clinically relevant TVEs were defined as deep vein thrombosis (DVT) of the limbs; thromboses of other major veins; pulmonary embolism (PE);acute coronary syndrome (ACS);ischemic stroke of arterial or cardiac origin; cerebral venous thrombosis; and arterial thrombosis. Objectively confirmed was defined as the confirmation of the clinical diagnosis of a TVE by appropriate medical imaging studies and laboratory tests.

Time frame:
from randomization through Week 16
Reported as:
Number · particpants
Number of Participants With at Least 1 Clinically Relevant and Objectively Confirmed Thrombovascular Event From Randomization Through Week 16
particpantsEpoetin Alfa QWEpoetin Alfa TIW
Number of Participants With at Least 1 Clinically Relevant and Objectively Confirmed Thrombovascular Event From Randomization Through Week 16510
Statistical analysis
  • Epoetin Alfa QW vs Epoetin Alfa TIW · Chi-squared · p = 0.248 · Risk difference (rd): -0.018 · 95% CI -0.051 to 0.016
  • Epoetin Alfa QW vs Epoetin Alfa TIW · Regression, Logistic · p = 0.254 · Odds ratio (or): 0.53 · 95% CI 0.18 to 1.58
SecondaryNumber of Positively Adjudicated Thrombovascular Events

The number of participants who have at least 1 clinically relevant and objectively confirmed (adjudicated) thrombovascular event (TVE) during the study.

Time frame:
during the study (randomization through week 26)
Reported as:
Number · participants
Number of Positively Adjudicated Thrombovascular Events
participantsEpoetin Alfa QWEpoetin Alfa TIW
Number of Positively Adjudicated Thrombovascular Events513
Statistical analysis
  • Epoetin Alfa QW vs Epoetin Alfa TIW · Chi-squared · p = 0.08 · Risk difference (rd): -0.029 · 95% CI -0.065 to 0.007
SecondaryTime to First Positively Adjudicated Thrombovascular Event

Analysis of time to first positively adjudicated thrombovascular event (TVE) measured from the date of randomization to the date of the first clinically relevant and objectively confirmed TVE as determined by the Adjudication Committee. Median time is non-estimable because of too few events, incidence was reported instead.

Time frame:
during the study (randomization through week 26)
Reported as:
Number · participants
Time to First Positively Adjudicated Thrombovascular Event
participantsEpoetin Alfa QWEpoetin Alfa TIW
Time to First Positively Adjudicated Thrombovascular Event513
Statistical analysis
  • Epoetin Alfa QW vs Epoetin Alfa TIW · Log Rank · p = 0.073 · Hazard ratio (hr): 0.40 · 95% CI 0.14 to 1.13The Cox regression model with covariates for treatment group and Eastern Cooperative Oncology Group (ECOG) performance status (0 or 1 versus 2) was used for estimates of hazard ratio and its 95% confidence interval.
SecondaryNumber of Suspected Thrombovascular Events

Number of participants who have at least 1 suspected thrombovascular events (TVEs) during the entire study. Suspected TVEs were defined as suspected TVEs during the entire study, whether clinically relevant and objectively confirmed by the Adjudication Committee or not, whether confirmed by the investigator or not.

Time frame:
during the study (randomization through week 26)
Reported as:
Number · participants
Number of Suspected Thrombovascular Events
participantsEpoetin Alfa QWEpoetin Alfa TIW
Number of Suspected Thrombovascular Events920
Statistical analysis
  • Epoetin Alfa QW vs Epoetin Alfa TIW · Chi-squared · p = 0.059 · Risk difference (rd): -0.039 · 95% CI -0.083 to 0.005
SecondaryTime to First Suspected Thrombovascular Event

Analysis of time to first suspected thrombovascular event (TVE) measured from the date of randomization to the date of the first suspected TVE during the study. Median time is non-estimable because of too few events, incidence was reported instead.

Time frame:
during the study (randomization through week 26)
Reported as:
Number · participants
Time to First Suspected Thrombovascular Event
participantsEpoetin Alfa QWEpoetin Alfa TIW
Time to First Suspected Thrombovascular Event920
Statistical analysis
  • Epoetin Alfa QW vs Epoetin Alfa TIW · Log Rank · p = 0.054 · Hazard ratio (hr): 0.47 · 95% CI 0.21 to 1.03The Cox regression model including covariates for treatment group and the Eastern Cooperative Oncology Group (ECOG) score status (0 or 1 versus 2) was used for estimates of a hazard ratio and its 95% confidence interval.
SecondaryMortality

Number of participants who died during the study.

Time frame:
during the study (randomization through week 26)
Reported as:
Number · participants
Mortality
participantsEpoetin Alfa QWEpoetin Alfa TIW
Mortality2526
Statistical analysis
  • Epoetin Alfa QW vs Epoetin Alfa TIW · Chi-squared · p = 0.88 · Risk difference (rd): 0.0041 · 95% CI -0.0526 to 0.0608
SecondaryNumber of Hemoglobin Responders

Hemoglobin response was defined as a hemoglobin increase of ≥2 g/dL from baseline or reaching a hemoglobin concentration of 12 g/dL, regardless of dose adjustment.

Time frame:
during the study (randomization through week 26)
Reported as:
Number · participants
Number of Hemoglobin Responders
participantsEpoetin Alfa QWEpoetin Alfa TIW
Number of Hemoglobin Responders179187
Statistical analysis
  • Epoetin Alfa QW vs Epoetin Alfa TIW · Chi-squared · p = 0.514 · Risk difference (rd): 0.026 · 95% CI -0.056 to 0.108
SecondaryRed Blood Cell Transfusions

The number of participants who received at least 1 red blood cell (RBC) transfusion (packed RBC or whole blood) during the study.

Time frame:
during the study (randomization through week 26)
Reported as:
Number · participants
Red Blood Cell Transfusions
participantsEpoetin Alfa QWEpoetin Alfa TIW
Red Blood Cell Transfusions3842
Statistical analysis
  • Epoetin Alfa QW vs Epoetin Alfa TIW · Chi-squared · p = 0.920 · Risk difference (rd): -0.003 · 95% CI -0.071 to 0.065

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Epoetin Alfa QW—53/242 (21.9%)157/242 (64.9%)
Epoetin Alfa TIW—64/262 (24.4%)151/262 (57.6%)
Most frequent serious events
Showing 10 of 90
Most frequent serious events
EventEpoetin Alfa QWEpoetin Alfa TIW
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)19/24220/262
PneumoniaInfections and infestations2/2429/262
AnaemiaBlood and lymphatic system disorders4/2422/262
Febrile neutropeniaBlood and lymphatic system disorders4/2420/262
ThrombocytopeniaBlood and lymphatic system disorders1/2424/262
Deep vein thrombosisVascular disorders3/2424/262
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/2424/262
LeukopeniaBlood and lymphatic system disorders3/2421/262
NeutropeniaBlood and lymphatic system disorders2/2423/262
PancytopeniaBlood and lymphatic system disorders2/2421/262
Most frequent other events
Showing 10 of 11
Most frequent other events
EventEpoetin Alfa QWEpoetin Alfa TIW
NeutropeniaBlood and lymphatic system disorders81/24272/262
ThrombocytopeniaBlood and lymphatic system disorders52/24254/262
LeukopeniaBlood and lymphatic system disorders51/24244/262
NauseaGastrointestinal disorders27/24240/262
DiarrhoeaGastrointestinal disorders26/24210/262
VomitingGastrointestinal disorders13/24224/262
AstheniaGeneral disorders21/24214/262
FatigueGeneral disorders17/24216/262
PyrexiaGeneral disorders15/24218/262
AnorexiaMetabolism and nutrition disorders13/24211/262

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Epoetin Alfa QWEpoetin Alfa TIWTotal
<=18 years112
Between 18 and 65 years160173333
>=65 years8188169
Age Continuous
Age Continuous(years)Epoetin Alfa QWEpoetin Alfa TIWTotal
Mean58.8 ± 13.3557.5 ± 13.5358.1 ± 13.44
Sex: Female, Male
Sex: Female, Male(Participants)Epoetin Alfa QWEpoetin Alfa TIWTotal
Female156181337
Male8681167
Region of Enrollment
Region of Enrollment(participants)Epoetin Alfa QWEpoetin Alfa TIWTotal
Bulgaria6713
France7613
Germany5155106
Great Britain145
Greece81220
Italy131326
Poland7613
Romania212041
Russia8893181
Slovakia91120
Ukraine313566
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2011, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2010
First posted
Jul 15, 2011
Start
Jan 2006
Primary completionActual
Sep 2009
CompletionActual
Sep 2009
Results first posted
Jul 15, 2011
Last update
Apr 5, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01394991
First posted
Jul 15, 2011
Start date
Jan 2006
Primary completion
Sep 2009
Completion
Sep 2009
Results posted
Jul 15, 2011
Last update
Apr 5, 2012

Study contacts

Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial
study director · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epoetin Alfa

Start the discussion